Lumos Diagnostics Holdings (LDX) Stock Overview
Develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lumos Diagnostics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.24 |
| 52 Week High | AU$0.30 |
| 52 Week Low | AU$0.02 |
| Beta | 0.64 |
| 1 Month Change | 32.43% |
| 3 Month Change | 40.00% |
| 1 Year Change | 620.59% |
| 3 Year Change | 432.61% |
| 5 Year Change | n/a |
| Change since IPO | -81.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -12.5% | -2.5% | -0.06% |
| 1Y | 620.6% | -8.0% | 3.3% |
Return vs Industry: LDX exceeded the Australian Medical Equipment industry which returned -8% over the past year.
Return vs Market: LDX exceeded the Australian Market which returned 3.3% over the past year.
Price Volatility
| LDX volatility | |
|---|---|
| LDX Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 11.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 18.3% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: LDX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: LDX's weekly volatility has decreased from 25% to 18% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Doug Ward | lumosdiagnostics.com |
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
Lumos Diagnostics Holdings Limited Fundamentals Summary
| LDX fundamental statistics | |
|---|---|
| Market cap | AU$196.80m |
| Earnings (TTM) | -AU$10.86m |
| Revenue (TTM) | AU$18.74m |
Is LDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDX income statement (TTM) | |
|---|---|
| Revenue | US$12.40m |
| Cost of Revenue | US$4.72m |
| Gross Profit | US$7.68m |
| Other Expenses | US$14.86m |
| Earnings | -US$7.18m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0091 |
| Gross Margin | 61.93% |
| Net Profit Margin | -57.93% |
| Debt/Equity Ratio | 0% |
How did LDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/17 18:55 |
| End of Day Share Price | 2025/12/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lumos Diagnostics Holdings Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |